ASCEND: A Study of Cardiovascular Events iN Diabetes
Status:
Active, not recruiting
Trial end date:
2037-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or
supplementation with 1 gram daily omega-3 fatty acids or placebo prevents "serious vascular
events" (i.e. non-fatal heart attack, non-fatal stroke or transient ischaemic attack, or
death from vascular causes) in patients with diabetes who are not known to have occlusive
arterial disease and to assess the effects on serious bleeding or other adverse events.
Phase:
Phase 4
Details
Lead Sponsor:
University of Oxford
Collaborators:
Abbott Abbott Products Bayer British Heart Foundation Medical Research Council Mylan Solvay Pharmaceuticals